Related Experiment Videos
Administration of a retinoid as prophylaxis of recurrent non-invasive bladder tumors
Abstract:
A controlled study has been conducted to ascertain whether administration for 8 months of a vitamin A-acid analog, Tigason, could prevent recurrences of non-invasive bladder tumors. Eligible were 73 patients, 33 in the Tigason group, and 40 in the placebo group. The results indicate that Tigason, as used in this study, is ineffective as prophylaxis. Side effects to Tigason urged 17 patients to drop out from the study mostly due to symptoms from skin and mucous membranes. The discussion considers different reasons for the lack of effect and concludes that more tolerable vitamin A-acid analogs are needed if further studies of prevention of non-invasive bladder tumors are to be carried out.
Insights
This study found Tigason ineffective for preventing non-invasive bladder tumor recurrence. Side effects led to many patient dropouts, highlighting the need for better vitamin A-acid analogs.
Area of Science:
- Oncology
- Dermatology
- Urology
Background:
- Non-invasive bladder tumors have a high recurrence rate.
- Preventive strategies are crucial for managing bladder cancer.
- Vitamin A and its analogs are investigated for chemoprevention.
Purpose of the Study:
- To evaluate the efficacy of Tigason (a vitamin A-acid analog) in preventing the recurrence of non-invasive bladder tumors.
- To assess the safety and tolerability of Tigason in this patient population.
Main Methods:
- A controlled study involving 73 patients with a history of non-invasive bladder tumors.
- Patients were randomized to receive either Tigason or a placebo for 8 months.
- Recurrence rates and adverse events were monitored.
Main Results:
- Tigason did not demonstrate effectiveness in preventing bladder tumor recurrence.
- A significant number of patients (17) withdrew due to adverse effects, primarily skin and mucous membrane issues.
- The study suggests Tigason, at the tested dosage and duration, is not a viable prophylactic treatment.
Conclusions:
- Current use of Tigason is ineffective for preventing non-invasive bladder tumor recurrence.
- The high incidence of side effects limits its clinical utility.
- Development of more tolerable vitamin A-acid analogs is necessary for future chemoprevention research in bladder cancer.